All news articles for February 2021

© GettyImages/image_jungle

Celltrion secures EU approval for its adalimumab biosimilar

By Jane Byrne

Celltrion’s adalimumab biosimilar, Yuflyma (CT-P17) has been approved by the European Commission for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.

Follow us

Products

View more

Webinars